Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C46H77NO17 |
Molecular Weight | 916.1001 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]2[C@@H](C)O[C@@]([H])(O[C@H]3[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@H](CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC)[C@@H](CC)OC(=O)C[C@@H](O)[C@@H]3C)[C@H](O)[C@H]2N(C)C
InChI
InChIKey=WBPYTXDJUQJLPQ-VMXQISHHSA-N
InChI=1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3/b15-14+,23-18+/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-/m1/s1
Molecular Formula | C46H77NO17 |
Molecular Weight | 916.1001 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm091554.pdfCurator's Comment: Description was created based on several sources, including https://www.elanco.us/labels/Swine/Tylan_Soluble.pdf
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm091554.pdf
Curator's Comment: Description was created based on several sources, including https://www.elanco.us/labels/Swine/Tylan_Soluble.pdf
Tylosin (trade names Tylocine, Tylan) is a bacteriostat feed additive used in veterinary medicine. It has a broad spectrum of activity against Gram-positive organisms and a limited range of Gram-negative organisms. It is found naturally as a fermentation product of Streptomyces fradiae. It is a macrolide antibiotic. Tylosin is used in veterinary medicine to treat bacterial infections in a wide range of species and has a high margin of safety. Tylosin is certified by the FDA but is only approved for use in livestock such as cattle, chickens, swine, and turkeys. The FDA has prohibited the use of tylosin in dogs and cats, except where it is specifically prescribed by a veterinarian. Tylosin has a bacteriostatic effect on susceptible organisms, caused by inhibition of protein synthesis through binding to the 50S subunit of the bacterial ribosome.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Mycoplasma sp. 1220 growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/27543140 |
|||
Target ID: Staphylococcus aureus growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/14711312 |
|||
Target ID: E. coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/14711312 |
|||
Target ID: Streptococcus pneumoniae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/14711312 |
|||
Target ID: Pasteurella multocida growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/9135031 |
|||
Target ID: Fusobacterium necrophorum growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3398001 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Tylan 200 Approved UseIn beef cattle and non-lactating dairy cattle, Tylan 200 Injection is indicated for use in the treatment of bovine respiratory complex (shipping fever, pneumonia) usually associated with Pasteurella multocida and Actinomyces pyogenes; foot rot (necrotic pododermatitis) and calf diphtheria caused by Fusobacterium necrophorum and metritis caused by Actinomyces pyogenes.
In swine, Tylan 200 Injection is indicated for use in the treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by appropriate medication in the drinking water and/or feed. Launch Date2010 |
|||
Curative | Tylan 200 Approved UseIn beef cattle and non-lactating dairy cattle, Tylan 200 Injection is indicated for use in the treatment of bovine respiratory complex (shipping fever, pneumonia) usually associated with Pasteurella multocida and Actinomyces pyogenes; foot rot (necrotic pododermatitis) and calf diphtheria caused by Fusobacterium necrophorum and metritis caused by Actinomyces pyogenes.
In swine, Tylan 200 Injection is indicated for use in the treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by appropriate medication in the drinking water and/or feed. Launch Date2010 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/tylan-50.html
Curator's Comment: Can also be given orally https://www.elanco.us/labels/Swine/Tylan_Soluble.pdf
BEEF CATTLE AND NON-LACTATING DAIRY CATTLE—Inject intramuscularly 8 mg per pound of body weight one time daily (1 mL per 6.25 pounds). Treatment should be continued 24 hours following remission of disease signs, not to exceed 5 days.
SWINE—Inject intramuscularly 4 mg per pound of body weight (1 mL per 12.5 pounds) twice daily. Treatment should be continued 24 hours following remission of disease signs, not to exceed 3 days. Do not inject more than 5 mL per site.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/27543140
Tylosin yielded MIC50 value for Mycoplasma sp. 1220 strain isolated from geese in Hungary - 8 ug/ml
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:47:37 GMT 2023
by
admin
on
Fri Dec 15 15:47:37 GMT 2023
|
Record UNII |
YEF4JXN031
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 558.625
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
CFR |
21 CFR 558.630
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
CFR |
21 CFR 556.740
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
CFR |
21 CFR 522.2640
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
NCI_THESAURUS |
C261
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
WHO-VATC |
QJ01FA90
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
WHO-VATC |
QJ51FA90
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
FDA ORPHAN DRUG |
572916
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
CFR |
21 CFR 520.2640
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
YEF4JXN031
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
TYLOSIN
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
DB11475
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
1703805
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
1401-69-0
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
2109
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
77047
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
D015645
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
YEF4JXN031
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
5280440
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
C84234
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
995505
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
17658
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
215-754-8
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
DTXSID3043996
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
7022
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
m11283
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL42743
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
DERIVATIVE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |